Lighting the way to host-directed immunotherapeutics

Area of Science:

• Virology
• Drug Discovery
• Immunology

Background:

• Emerging viral threats necessitate the development of broad-spectrum antiviral therapeutics.
• Host-directed therapies offer a promising strategy by targeting host pathways rather than viral components.

Purpose of the Study:

• To screen for small molecules that can act as host-directed antiviral agents.
• To identify compounds that enhance the host immune response against viral infections.

Main Methods:

• Utilized a Nano luciferase reporter-based protein complementation assay for high-throughput screening.
• Screened a library of small molecules to identify compounds with antiviral properties.

Main Results:

• Identified Gilteritinib as a potent small molecule with broad-spectrum antiviral activity.
• Demonstrated that Gilteritinib enhances interferon induction in host cells.
• Showed that Gilteritinib antagonizes viral replication through host-directed mechanisms.

Conclusions:

• Gilteritinib is a promising candidate for a host-directed antiviral therapeutic.
• The Nano luciferase reporter assay is effective for identifying antiviral compounds.
• Targeting host interferon pathways offers a viable strategy for combating emerging viruses.